Hengrui Unit Gets NMPA Approval for HRS-1780 Phase II/III Trial in Uncontrolled or Resistant Hypertension
Hengrui Medicine's subsidiary Shandong Shengdi Pharmaceutical received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-1780 tablets, approving the conduct of Phase II/III clinical trials. The trial is for the treatment of uncontrolled hypertension or resistant hypertension. HRS-1780 tablets are a mineralocorticoid receptor antagonist, and currently no similar product is on the market in China. The cumulative R&D investment for this project is about RMB 100 million.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 60/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.